You are here

  • Home
  • Archive
  • Volume 10, Issue 10
  • Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Citation Tools

Article menu
XML
Neurology
Original research
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Butzkueven H, Licata S, Jeffery D on behalf of the REVEAL Investigators, et al
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
BMJ Open 2020;10:e038861. doi: 10.1136/bmjopen-2020-038861